share_log

Applied DNA Biotherapeutics Subsidiary Reports LinearDNA Platform Development Milestone: First Successful Administration Of LinearDNA In Vivo Via Lipid Nanoparticles (LNP)

Benzinga Real-time News ·  Aug 10, 2022 09:34

Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, the Company's majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular (IM) injection without the concurrent use of electroporation (EP) that utilizes electrical pulses to deliver DNA to target cells. The Company believes that the removal of the concurrent use of EP during administration potentially increases the commercial viability of LinearDNA-based therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment